PRISMA Scoping Review Examines Food-Drug Interactions in Cardiovascular and Diabetic Medications
Meals May Not Matter for Most New Heart and Diabetes Pills
This PRISMA scoping review synthesized data from 36 publications regarding food-drug interactions in cardiovascular and diabetic medications…
Most new heart and diabetes pills work the same whether you take them with food or on an empty stomach, but a few still need timing.
Concurrent anti-VEGF and anticoagulant use in cancer patients with VTE shows rare bleeding events
Can You Take Blood Thinners With Cancer Drugs Safely?
This retrospective analysis at Hunan Cancer Hospital assessed 208 patients receiving concurrent anti-VEGF agents and anticoagulants for VTE.…
New research suggests it is generally safe to use blood thinners with certain cancer treatments.
Network meta-analysis compares prophylactic anticoagulants for central venous catheter-related thrombosis in cancer patients.
Cancer Patients May Avoid Clots With Safer Blood Thinner
This network meta-analysis synthesizes data from 19 clinical studies regarding prophylactic anticoagulation in cancer patients with central …
A new analysis shows one specific blood thinner may protect cancer patients from dangerous clots with fewer side effects.
Genetic polymorphisms influence pharmacokinetics and bleeding risk for DOACs in meta-analysis
Your DNA May Explain Why Blood Thinners Work Differently for You
A meta-analysis of 39 studies involving 13,300 patients found that genetic polymorphisms (e.g., CES1, ABCB1) are associated with pharmacokin…
Tiny DNA differences may explain why the same blood thinner protects one person but causes bleeding in another.
Adding low-dose rivaroxaban to DAPT did not significantly reduce LV thrombus in anterior STEMI patients.
Adding low-dose rivaroxaban to standard heart attack drugs did not clearly prevent blood clots in the heart
This randomized clinical trial evaluated 560 patients with anterior ST-segment elevation myocardial infarction (STEMI) across 29 centers in …
Adding a low-dose blood thinner to standard heart attack drugs did not clearly prevent dangerous clots in the heart, based on a trial of 560…
Proceeding with TKA without preoperative anticoagulation for asymptomatic calf vein thrombosis shows no 90-day VTE events
Skip the delay for a minor clot before knee surgery
A retrospective cohort study of 454 adults undergoing primary unilateral TKA found that 44 patients with preoperative asymptomatic isolated …
A small, silent clot found before knee replacement does not require stopping surgery or adding extra blood thinners.
Post-hoc analysis links lower systolic BP to higher cardiovascular risk in AF and stable CAD
Lower blood pressure linked to higher risk in AF patients with heart disease
A post-hoc analysis of the AFIRE trial (n=2135) found patients with atrial fibrillation and stable coronary artery disease who had baseline …
Patients with atrial fibrillation and low blood pressure face a 38% higher risk of heart attack, stroke, or death compared to those with hig…
FDA Approves Xarelto (rivaroxaban) for multiple indications including stroke prevention in nonvalvular atrial fibrillation and treatment of VTE.
FDA approves a new blood thinner called Xarelto for several heart and clot conditions.
The FDA approved rivaroxaban (Xarelto), a factor Xa inhibitor, for multiple indications including reducing stroke risk in nonvalvular atrial…
FDA approves new blood thinner Xarelto to prevent dangerous clots in heart conditions, deep vein issues, and after major surgeries.
FDA Approves Xarelto (rivaroxaban) for Thromboprophylaxis in Pediatric Patients After Fontan Procedure
FDA approves Xarelto to help prevent blood clots in children with certain heart conditions.
The FDA approved rivaroxaban (Xarelto) for thromboprophylaxis in pediatric patients aged 2 years and older with congenital heart disease who…
FDA approves Xarelto to prevent dangerous blood clots in children aged 2 and older born with heart defects who have had Fontan surgery.
TRACK trial to assess low-dose rivaroxaban for MACE in advanced CKD/dialysis patients
Can a low-dose blood thinner protect people with advanced kidney disease from heart attacks and strokes?
The TRACK trial is a global, quadruple-blind, placebo-controlled phase 3 study evaluating low-dose rivaroxaban (2.5 mg) for reducing major a…
A new global study tested whether a low-dose blood thinner safely protects people with advanced kidney disease from heart attacks and stroke…